[Plasminogen activators and thrombolytic therapy].
The mechanism of plasminogen activation by streptokinase, tissue and urokinase-type plasminogen activators (PAs) were reviewed. The regulatory role of fibrin in plasminogen activation involving its direct interaction with tissue-type PA and indirect interaction with streptokinase and urokinase-type PAs was demonstrated. Recent information on the development of new PAs is also displayed. The result of studies of PA mutant derivatives synthesized by recombinant DNA techniques are discussed. Date on chimeric (hybrid) forms of PAs and their chemically synthesized conjugates are presented. The trend in search for PAs is analysed. A new direction in the study of PAs for combined plasminogen activation and the further development of the methods of thrombolytic therapy was outlined.
Taran
L D
LD
D006801:Humans; D010960:Plasminogen Activators / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D015202:Protein Engineering; D011498:Protein Precursors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D013300:Streptokinase / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism / Q000627:therapeutic use
D011498:Protein Precursors; D011994:Recombinant Proteins; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator